Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: Providing Suboxone and PrEP Using Telemedicine [NA]
Completed clinical trial evaluating telemedicine provision of Suboxone and PrEP for opioid use disorder with results posted in 2023.
-
FDA approval · 2023-06-06FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for a buprenorphine hydrochloride and naloxone hydrochloride dihydrate product from Hikma Pharma…
-
FDA approval · 2023-06-05FDA Approved: BUPRENORPHINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' supplemental application for buprenorphine.
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: Smartphone Technology to Alleviate Malignant Pain (STAMP) [NA]
A completed clinical trial evaluating smartphone technology (STAMP) for alleviating malignant pain in cancer patients; results posted in 202…
-
FDA approval · 2023-06-02FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Buprenorphine and Naloxone (buprenorphine/naloxone) from Sun Pharmaceutical Industries, Inc. und…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-26Clinical Trial Update: CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder [NA]
Completed clinical trial evaluating a combined medication and behavioral activation treatment for people with opioid use disorder, with resu…
-
FDA approval · 2023-05-25FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal Pharmaceuticals LLC's supplemental application for a generic buprenorphine HCl and naloxone HCl product for the treatmen…
-
FDA approval · 2023-05-23FDA Approved: BRIXADI — Original Application (Braeburn Inc.)
FDA approves BRIXADI (buprenorphine) from Braeburn Inc. under an original application to treat opioid use disorder; BRIXADI is an extended-r…
-
FDA approval · 2023-05-23FDA Approved: BUPRENORPHINE AND NALOXONE SUBLINGUAL FILM — Supplemental Application (Alvogen Inc.)
FDA approved a supplemental application for buprenorphine and naloxone sublingual film by Alvogen Inc.
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine [Phase 2]
A Phase 2 clinical trial evaluating cannabidiol to reduce cravings in individuals with opioid use disorder on buprenorphine has completed an…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection [Phase 4]
Phase 4 clinical trial update for Sofosbuvir/Velpatasvir in postpartum women with opioid use disorder and chronic hepatitis C infection; stu…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Rapid Initiation of Drug Treatment Engagement [Phase 4]
Phase 4 clinical trial on rapid initiation of drug treatment engagement for opioid use disorder; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Fathering In Recovery [NA]
Completed clinical trial related to parenting in individuals with opioid-use disorder; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Substance Use Treatment and Recovery Team (START) [NA]
A completed clinical trial (START) sponsored by RAND for opioid-use disorder and related conditions, with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Leveraging Social Networks to Increase COVID-19 Testing Uptake [NA]
A completed clinical trial evaluated using social networks to increase COVID-19 testing uptake among individuals with substance use and opio…
-
FDA approval · 2023-03-23FDA Approved: ZUBSOLV — Supplemental Application (Orexo US, Inc.)
The FDA approved a supplemental application for ZUBSOLV, a buprenorphine/naloxone product from Orexo US, Inc.
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine [Phase 2, Phase 3]
A clinical trial update investigating linkage to opioid use disorder treatment at sexual health clinics using buprenorphine, currently in Ph…
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Reward-Based Recovery Outcomes Management for Opioid Use Disorder [NA]
A completed clinical trial studying reward-based recovery outcomes management for opioid use disorder; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: SMART Trial: Intrapersonal and Interpersonal Stigma Reduction [Phase 2]
Phase 2 clinical trial update on the SMART trial assessing intrapersonal and interpersonal stigma reduction for opioid use-related stigma an…
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption [Phase 4]
A Phase 4 clinical trial evaluating whether simplified and more detailed postoperative instructions influence narcotic consumption; the stud…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Opioid Use Disorder in the Emergency Department: CTN 0069 [NA]
Clinical trial update for CTN 0069 studying opioid use disorder in the emergency department has completed and posted results.
-
CLINICAL_TRIALS research · 2023-02-10Clinical Trial Update: Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study [NA]
Phase I clinical trial evaluating a mobile medication adherence platform for buprenorphine-naloxone in treating opioid use disorder; study c…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: BRIDGE Percutaneous Nerve Stimulation for Cesarean Delivery Pain Control [NA]
Clinical trial update for BRIDGE Percutaneous Nerve Stimulation aimed at postoperative pain control in cesarean delivery; study status compl…
-
FDA approval · 2023-01-06FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine) from Indivior Inc., authorizing changes requested in the supplemen…
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: CBT4CBT for Office Based Buprenorphine [Phase 1, Phase 2]
Clinical trial update for CBT4CBT adjunctive therapy in office-based buprenorphine treatment for opioid-use disorder has completed Phase 1 a…